SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 16, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced the launch of the new Afirma Xpression Atlas, an RNA sequencing-based test that provides extensive genomic information to aid in surgery and treatment decisions for patients with potentially
Multiple Abstracts Showcasing “Real-World” Performance of the Afirma Genomic Sequencing Classifier also to be Presented SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 10, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will commercially launch its Afirma Xpression Atlas and present
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the 2018 UBS Global Healthcare Conference on Wednesday, May 23, 2018 at 9:00 a.m. Eastern Time in New York, NY .
Grew Revenue by 22%, to $20.0 Million Executed In-Network Contract with Anthem Company Raises 2018 Annual Revenue Guidance Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 1, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 17, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will report its first quarter 2018 financial results after the close of market on Tuesday, May 1, 2018 . Following the announcement, Veracyte will host a conference call and webcast
Agreement Leverages Veracyte’s New Afirma Xpression Atlas Platform SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 11, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced a research collaboration through which Loxo Oncology will access Veracyte’s new Afirma ® Xpression Atlas platform to
RNA Sequencing-Based Platform Will Provide Extensive Genomic Content to Help Inform Surgery and Treatment Decisions for Patients with Suspected Thyroid Cancer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that its soon-to-be-launched
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at ENDO 2018, the annual meeting of the Endocrine Society , suggest that the Afirma Genomic Sequencing Classifier (GSC) can help significantly more patients avoid
Company to Unveil New Afirma Xpression Atlas Platform SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 14, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data will be presented at ENDO 2018, the annual meeting of the Endocrine Society , underscoring the ability of the Afirma
Full-Year Revenue Grew 11%, to $72.0 Million Announces Upcoming Launch of Afirma Xpression Atlas Platform Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 27, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results and business
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
